{"entity":{"id":"nct02972840","kind":"trial","name":"A Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCL","aka":["ECHO","Acalabrutinib with bendamustine and rituximab in untreated mantle cell lymphoma"],"tldr":"A phase 3 trial of Acalabrutinib, Bendamustine and Rituximab in mantle cell lymphoma, run by Acerta Pharma BV, active and no longer recruiting.","summary":"A Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCL is a phase 3 interventional study registered as NCT02972840 by Acerta Pharma BV, with 635 participants enrolled, started 2017-04-05 and due to reach its primary completion in 2027-02-15. Interventions recorded: Acalabrutinib, Bendamustine, Rituximab and Placebo.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT02972840","url":"https://clinicaltrials.gov/study/NCT02972840"}],"tags":["pipeline","ctgov-ingest"],"related":["lymphoma-roadmap","paper-echo-acalabrutinib-bendamustine-rituximab-mantle-cell-jco-2025","shine","enrich"],"cancers":["mantle-cell-lymphoma"],"sections":[],"technologies":["cytotoxic-chemotherapy","kinase-inhibitors","monoclonal-antibody"],"targets":["btk","cd20","ccnd1"],"drugs":["acalabrutinib","bendamustine","rituximab"],"companies":["astrazeneca"],"institutions":[],"pathways":["bcr-signalling"],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-echo-acalabrutinib-bendamustine-rituximab-mantle-cell-jco-2025"],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT02972840","phase":"3","setting":"A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination With Acalabrutinib (ACP-196) in Subjects With Previously Untreated Mantle Cell Lymphoma","sponsor":"Acerta Pharma BV","result":"Median progression-free survival 66.4 against 49.6 months (hazard ratio 0.73, p = 0.0160), with no significant overall survival difference (hazard ratio 0.86, p = 0.27).","started":"2017-04-05","startedType":"actual","yearReported":2025,"enrolled":635,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct02972840/","neighbours":{"roadmap":[{"id":"lymphoma-roadmap","kind":"roadmap","name":"Lymphoma roadmap: from a jaw tumour in Uganda and the first human cancer virus to gene-expression subtypes, PET-adapted chemotherapy, CAR-T cells, bispecific antibodies and the genetics-directed trials now recruiting","route":"/roadmaps/lymphoma-roadmap/"}],"paper":[{"id":"paper-echo-acalabrutinib-bendamustine-rituximab-mantle-cell-jco-2025","kind":"paper","name":"Acalabrutinib plus bendamustine-rituximab in untreated mantle cell lymphoma","route":"/key-papers/paper-echo-acalabrutinib-bendamustine-rituximab-mantle-cell-jco-2025/"},{"id":"paper-shine-ibrutinib-bendamustine-rituximab-mantle-cell-nejm-2022","kind":"paper","name":"Ibrutinib plus bendamustine and rituximab in untreated mantle-cell lymphoma","route":"/key-papers/paper-shine-ibrutinib-bendamustine-rituximab-mantle-cell-nejm-2022/"}],"trial":[{"id":"enrich","kind":"trial","name":"ENRICH","route":"/trials/enrich/"},{"id":"shine","kind":"trial","name":"SHINE","route":"/trials/shine/"}],"cancer":[{"id":"mantle-cell-lymphoma","kind":"cancer","name":"Mantle cell lymphoma","route":"/cancers/mantle-cell-lymphoma/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"},{"id":"monoclonal-antibody","kind":"technology","name":"Monoclonal antibodies","route":"/technologies/monoclonal-antibody/"},{"id":"kinase-inhibitors","kind":"technology","name":"Small-molecule kinase inhibitors","route":"/technologies/kinase-inhibitors/"}],"target":[{"id":"btk","kind":"target","name":"BTK (Bruton tyrosine kinase)","route":"/targets/btk/"},{"id":"ccnd1","kind":"target","name":"CCND1","route":"/targets/ccnd1/"},{"id":"cd20","kind":"target","name":"CD20","route":"/targets/cd20/"}],"drug":[{"id":"acalabrutinib","kind":"drug","name":"Acalabrutinib","route":"/drugs/acalabrutinib/"},{"id":"bendamustine","kind":"drug","name":"Bendamustine","route":"/drugs/bendamustine/"},{"id":"rituximab","kind":"drug","name":"Rituximab","route":"/drugs/rituximab/"}],"company":[{"id":"astrazeneca","kind":"company","name":"AstraZeneca","route":"/companies/astrazeneca/"}],"pathway":[{"id":"bcr-signalling","kind":"pathway","name":"B-cell receptor / BTK signalling (to NF-κB)","route":"/pathways/bcr-signalling/"}]}}